Dr Mark P. Lythgoe is an Academic Clinical Fellow in Medical Oncology and Pharmacist. He is currently undertaking a PhD (primary supervisor Dr Jonathan Krell) exploring the cancer microbiome and live oral biotherapeutics as novel anti-cancer agents. Presently he oversees (principal investigator Dr Krell) the Imperial sponsored MICROBIOME trial (NCT03934827) with industry partner 4D Pharma exploring use of a live oral biotherapeutics (MRx0518) in patients with solid tumours awaiting surgical removal of the tumour.
After studying Pharmacy at Aston University, Mark went on to graduate with a duel distinction in Medicine from Kings College London. After completion of junior doctor posts in west London, he is now undertaking specialist academic training in Medical Oncology. He has also undertaken an academic clinical fellowship placement with Dr Rohini Sharma, exploring prognostic indices in high grade neuroendocrine tumours and PET imaging in a range of solid cancers, utilizing novel radionuclides to predict therapy responses.
He has a range of academic interests including translational clinical trial development, cancer microbiome modulation as a therapeutic strategy, healthcare policy, improving clinical trial access and meta-research. He has also been a member of the Joint Formulary Committee for the British National Formulary (BNF) for 8 years.
He received an American Society of Cancer Merit Award in 2021 and has authored papers in the JAMA Oncology, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, and Trends in Pharmacological Sciences. He also reviews manuscripts for several journals including Cancer, Scientific Reports, Trends in Pharmacological Sciences and European Journal of Cancer.
Lythgoe M, 2022, No new ‘mabs’ in medicine – New nomenclature for monoclonal antibodies, British Journal of Pharmacology, Vol:179, ISSN:0007-1188, Pages:5338-5339
et al., 2022, Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective, British Journal of Cancer, ISSN:0007-0920
Lythgoe M, Bower M, Krell J, 2022, From the European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit, The Lancet Oncology, ISSN:1213-9432
et al., 2022, 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy, SITC 37th Annual Meeting (SITC 2022) Abstracts, BMJ Publishing Group Ltd
et al., 2022, 427 Approval timings and review speed of immune checkpoint inhibitors (ICIs) in cancer therapy between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) from 2010-2022, SITC 37th Annual Meeting (SITC 2022) Abstracts, BMJ Publishing Group Ltd